193 related articles for article (PubMed ID: 26346403)
1. Significance of the Signal Intensity of Gadoxetic Acid-enhanced MR Imaging for Predicting the Efficacy of Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma.
Fujita N; Nishie A; Asayama Y; Ishigami K; Ushijima Y; Takayama Y; Okamoto D; Morita K; Shirabe K; Koto K; Kubo Y; Oda Y; Honda H
Magn Reson Med Sci; 2016; 15(1):111-20. PubMed ID: 26346403
[TBL] [Abstract][Full Text] [Related]
2. Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR Imaging--correlation with molecular transporters and histopathologic features.
Kitao A; Zen Y; Matsui O; Gabata T; Kobayashi S; Koda W; Kozaka K; Yoneda N; Yamashita T; Kaneko S; Nakanuma Y
Radiology; 2010 Sep; 256(3):817-26. PubMed ID: 20663969
[TBL] [Abstract][Full Text] [Related]
3. The uptake transporter OATP8 expression decreases during multistep hepatocarcinogenesis: correlation with gadoxetic acid enhanced MR imaging.
Kitao A; Matsui O; Yoneda N; Kozaka K; Shinmura R; Koda W; Kobayashi S; Gabata T; Zen Y; Yamashita T; Kaneko S; Nakanuma Y
Eur Radiol; 2011 Oct; 21(10):2056-66. PubMed ID: 21626360
[TBL] [Abstract][Full Text] [Related]
4. Hypervascular hepatocellular carcinoma: correlation between biologic features and signal intensity on gadoxetic acid-enhanced MR images.
Kitao A; Matsui O; Yoneda N; Kozaka K; Kobayashi S; Koda W; Gabata T; Yamashita T; Kaneko S; Nakanuma Y; Kita R; Arii S
Radiology; 2012 Dec; 265(3):780-9. PubMed ID: 23175543
[TBL] [Abstract][Full Text] [Related]
5. Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging.
Sun HY; Lee JM; Shin CI; Lee DH; Moon SK; Kim KW; Han JK; Choi BI
Invest Radiol; 2010 Feb; 45(2):96-103. PubMed ID: 20057319
[TBL] [Abstract][Full Text] [Related]
6. Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging.
Motosugi U; Ichikawa T; Sou H; Sano K; Tominaga L; Muhi A; Araki T
Radiology; 2010 Jul; 256(1):151-8. PubMed ID: 20574092
[TBL] [Abstract][Full Text] [Related]
7. Hepatocellular carcinoma: clinical significance of signal heterogeneity in the hepatobiliary phase of gadoxetic acid-enhanced MR imaging.
Fujita N; Nishie A; Kubo Y; Asayama Y; Ushijima Y; Takayama Y; Moirta K; Shirabe K; Aishima S; Honda H
Eur Radiol; 2015 Jan; 25(1):211-20. PubMed ID: 25063395
[TBL] [Abstract][Full Text] [Related]
8. Characterization of small (≤3 cm) hepatic lesions with atypical enhancement feature and hypointensity in hepatobiliary phase of gadoxetic acid-enhanced MRI in cirrhosis: A STARD-compliant article.
Shin SK; Kim YS; Choi SJ; Shim YS; Jung DH; Kwon OS; Choi DJ; Kim JH
Medicine (Baltimore); 2017 Jul; 96(29):e7278. PubMed ID: 28723741
[TBL] [Abstract][Full Text] [Related]
9. Hepatocellular carcinoma: imaging patterns on gadoxetic acid-enhanced MR Images and their value as an imaging biomarker.
Choi JW; Lee JM; Kim SJ; Yoon JH; Baek JH; Han JK; Choi BI
Radiology; 2013 Jun; 267(3):776-86. PubMed ID: 23401584
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic performance of gadoxetic acid-enhanced liver MR imaging in the detection of HCCs and allocation of transplant recipients on the basis of the Milan criteria and UNOS guidelines: correlation with histopathologic findings.
Lee DH; Lee JM; Baek JH; Shin CI; Han JK; Choi BI
Radiology; 2015 Jan; 274(1):149-60. PubMed ID: 25203131
[TBL] [Abstract][Full Text] [Related]
11. Hepatocellular carcinoma: hepatocyte-selective enhancement at gadoxetic acid-enhanced MR imaging--correlation with expression of sinusoidal and canalicular transporters and bile accumulation.
Tsuboyama T; Onishi H; Kim T; Akita H; Hori M; Tatsumi M; Nakamoto A; Nagano H; Matsuura N; Wakasa K; Tomoda K
Radiology; 2010 Jun; 255(3):824-33. PubMed ID: 20501720
[TBL] [Abstract][Full Text] [Related]
12. Gadoxetic acid-enhanced MR imaging for hepatocellular carcinoma: molecular and genetic background.
Kitao A; Matsui O; Yoneda N; Kozaka K; Kobayashi S; Koda W; Inoue D; Ogi T; Yoshida K; Gabata T
Eur Radiol; 2020 Jun; 30(6):3438-3447. PubMed ID: 32064560
[TBL] [Abstract][Full Text] [Related]
13. Histological grade of hepatocellular carcinoma correlates with arterial enhancement on gadoxetic acid-enhanced and diffusion-weighted MR images.
Chang WC; Chen RC; Chou CT; Lin CY; Yu CY; Liu CH; Chou JM; Hsu HH; Huang GS
Abdom Imaging; 2014 Dec; 39(6):1202-12. PubMed ID: 24869790
[TBL] [Abstract][Full Text] [Related]
14. Peri-tumoral hyperintensity on hepatobiliary phase of gadoxetic acid-enhanced MRI in hepatocellular carcinomas: correlation with peri-tumoral hyperplasia and its pathological features.
Yoneda N; Matsui O; Kitao A; Komori T; Kozaka K; Ikeda H; Yoshida K; Inoue D; Minami T; Koda W; Kobayashi S; Gabata T
Abdom Radiol (NY); 2018 Aug; 43(8):2103-2112. PubMed ID: 29260280
[TBL] [Abstract][Full Text] [Related]
15. Imaging features of subcentimeter hypointense nodules on gadoxetic acid-enhanced hepatobiliary phase MR imaging that progress to hypervascular hepatocellular carcinoma in patients with chronic liver disease.
Jang KM; Kim SH; Kim YK; Choi D
Acta Radiol; 2015 May; 56(5):526-35. PubMed ID: 24838304
[TBL] [Abstract][Full Text] [Related]
16. Differentiation of hepatic hyperintense lesions seen on gadoxetic acid-enhanced hepatobiliary phase MRI.
Suh YJ; Kim MJ; Choi JY; Park YN; Park MS; Kim KW
AJR Am J Roentgenol; 2011 Jul; 197(1):W44-52. PubMed ID: 21700994
[TBL] [Abstract][Full Text] [Related]
17. Gadoxetic acid-enhanced hepatobiliary phase MRI and high-b-value diffusion-weighted imaging to distinguish well-differentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease.
Lee MH; Kim SH; Park MJ; Park CK; Rhim H
AJR Am J Roentgenol; 2011 Nov; 197(5):W868-75. PubMed ID: 22021534
[TBL] [Abstract][Full Text] [Related]
18. Gadoxetate Disodium-Enhanced MRI to Differentiate Dysplastic Nodules and Grade of Hepatocellular Carcinoma: Correlation With Histopathology.
Channual S; Tan N; Siripongsakun S; Lassman C; Lu DS; Raman SS
AJR Am J Roentgenol; 2015 Sep; 205(3):546-53. PubMed ID: 26295640
[TBL] [Abstract][Full Text] [Related]
19. Value of gadoxetic acid-enhanced and diffusion-weighted MR imaging in evaluation of hepatocellular carcinomas with atypical enhancement pattern on contrast-enhanced multiphasic MDCT in patients with chronic liver disease.
Kim HS; Kim SH; Kang TW; Song KD; Choi D; Park CK
Eur J Radiol; 2015 Apr; 84(4):555-62. PubMed ID: 25617950
[TBL] [Abstract][Full Text] [Related]
20. Imaging Features of Gadoxetic Acid-enhanced and Diffusion-weighted MR Imaging for Identifying Cytokeratin 19-positive Hepatocellular Carcinoma: A Retrospective Observational Study.
Choi SY; Kim SH; Park CK; Min JH; Lee JE; Choi YH; Lee BR
Radiology; 2018 Mar; 286(3):897-908. PubMed ID: 29166246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
